Zürich researchers have published preclinical data in The Journal of Allergy and Clinical Immunology on a different type of solution against cat allergy: a vaccine that inoculates the cat, instead of the human.
The most common cat allergen is called "Fel d 1", produced largely by the cat's sebaceous glands and found in feline saliva, anal glands, sebaceous glands, skin and fur.
Fel-CuMVTT, which the Swiss company HypoPet will market as a vaccine HypoCat, has been developed through a collaboration between researchers from the Latvian Biomedical Research and Study Center, in Riga, and the veterinary school of the University of Zurich, together with scientists from the Center for Functional Genomics in Zurich.
The vaccine may produce high levels of antibodies in cats These antibodies can bind and neutralize the Fel d 1 allergen produced by animals.
In addition to reporting that the vaccine is effective, it is also reported that it has been "well tolerated without any manifest toxicity" for feline test subjects. Published data are obtained from four separate studies involving 54 cats..
The benefits of an effective treatment against cat allergy are twofold. First of all, these allergies are not only annoying, but it is understood that an allergy to cats in children is an important factor in the development of childhood asthma. A simple three dose vaccine treatment, as given in the tests, could alleviate the suffering of cat owners and the risk to children.